HIV-1 CRF63_02A6 models as a tool for evaluating efficacy of developing antiretroviral drugs

Cover Page

Cite item

Abstract

Highly active antiretroviral therapy (HAART) allows not only to control the infection process in certain patient, but also to reduce a risk of HIV infection spreading in general, so that one of the goals for international community fighting against HIV-spread is to maximize coverage of infected subjects with HAART. Antiretroviral therapy in HIV infection is administered lifelong, so that therapeutic efficacy may be lowered due to emergence of resistant HIV-1 variants. Currently, development of new antiretroviral drugs is currently underway throughout the world, therefore standard HIV-1 models are demanded to evaluate antiviral efficacy of promising drugs. To reliably assess drug efficiency regarding Russiawide HIV-1 variants, HIV-1 genovariants widespread in Russia should be used as a virus model. A recently emerged recombinant form of CRF63_02A6 HIV-1 is spread in Russia being currently a dominant variant detected among HIV-infected individuals in an extended region of the Siberian Federal District: in the Novosibirsk, Tomsk, Omsk, Kemerovo Regions, Krasnoyarsk and Altai Krai. We have obtained CRF63_02A6 infectious isolates of HIV-1, one of which contains mutations, reducing the sensitivity to the applied inhibitors of the virus reverse transcriptase. In addition, we constructed infectious molecular clones based on HIV-1 CRF63_02A6 variants with an affinity for CCR5 coreceptors and CXCR4. Infectious isolates and molecular clones CRF63_02A6 tested as models for assessing efficacy of antiretroviral drugs using the example of the drug “Efavirenz”. The fifty percent inhibitory concentration determined on the models of HIV-1 infectious molecular clones and HIV-1 isolate 18RU7056 ranged from 0.00027 pg/ml to 0.00046 pg/ml being in agreement with data published elsewhere. Concentrations of “Efavirenz” used in the study did not suppress the replication of HIV-1 12RU6987, which is resistant to non-nucleoside reverse transcriptase inhibitors, which confirms the decrease in the sensitivity of HIV-1 12RU6987 to “Efavirenz” by no less than 10,000 times. Thus, our data demonstrate that CRF63_02A6 HIV-1 isolated strains and infectious molecular clones are relevant and complementary tools for assessing efficacy of developing drugs aimed at suppressing HIV-1, including non-nucleoside-resistant virus reverse transcriptase inhibitors.

About the authors

D. P. Zyryanova

State Research Center of Virology and Biotechnology Vector

Email: zyryanova_dp@vector.nsc.ru

Junior Researcher, Department of Retroviruses.

Koltsovo

Russian Federation

N. V. Bogacheva

State Research Center of Virology and Biotechnology Vector

Email: unagaeva2009@ngs.ru

Junior Researcher, Department of Retroviruses.

Koltsovo

Russian Federation

A. V. Totmenin

State Research Center of Virology and Biotechnology Vector

Email: tot58@bk.ru

PhD (Biology), Head of the Laboratory, Department of Retroviruses.

Koltsovo

Russian Federation

N. M. Gashnikova

State Research Center of Virology and Biotechnology Vector

Author for correspondence.
Email: nmgashnikova@gmail.com
ORCID iD: 0000-0002-0891-0880

Natalya M. Gashnikova - PhD (Biology), Head of the Department of Retroviruses.

630559, Koltsovo, Novosibirsk region, Phone: +7 (383) 363-47-00, add. 21-40 (office); +7 913 940-54-79

Russian Federation

References

  1. Богачева Н.В., Бледных Н.А., Тотменин А.В., Мирджамалова Ф.О., Соколов Ю.В., Гашникова Н.М. Создание коллекции современных изолятов ВИЧ-1, включающей основные российские генетические варианты вируса // ВИЧ-инфекция и иммуносупрессии. 2017. Т. 9, № 1. С. 65—76. doi: 10.22328/2077-9828-2017-9-1-65-76(In Russ.)]
  2. ВИЧ-инфекция в Российской Федерации в 2018 г. М.: ФБУН Центрального НИИ эпидемиологии Роспотребнадзора, 2018. URL: http://www.aids43.ru/stat
  3. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козы-рина Н.В., Буравцова В.В., Нарсия Р.С., Хохлова О.Н., Покровская А.В., Ефремова О.С., Коннов В.В., Куимова У.А., Попова А.А., Воронин Е.Е., Афонина Л.Ю., Васильева И.А., Зимина В.Н. Национальные рекомендации по диспансерному наблюдению и лечению больных ВИЧ-инфекцией. Клинический протокол // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2017. № 6.
  4. Прокофьева М.М., Спирин П.В., Январев Д.В., Иванов А.В., Новиков М.С., Степанов О.А., Готтих М.Б., Кочетков С.Н., Fehse B., Stocking C., Прасолов В.С. Скрининг потенциальных ингибиторов/блокаторов репликации ВИЧ-1 с помощью безопасной лентивирусной системы in vitro // Acta Naturae. 2011. Т. 3, № 4. С. 57—67.
  5. Baalwa J., Wang S., Parrish N.F., Decker J.M., Keele B.F., Learn G.H., Yue L., Rugazigira E., Ssemwanga D., Kamali A. Molecular identification, cloning and characterization oftransmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology, 2013, vol. 436, no. 1,pp. 33—48. doi: 10.1016/j.virol.2012.10.009
  6. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., Hakim J.G., Kumwenda J., Grinsztejn B., Pilotto J.H., Godbole S.V., Chariyalertsak S., Santos B.R., Mayer K.H., Hoffman I.F., Eshleman S.H., Piwowar-Manning E., Cottle L., Zhang X.C., Makhema J., Mills L.A., Panchia R., Faesen S., Eron J., Gallant J., Havlir D., Swindells S., Elharrar V., Burns D., Taha T.E., Nielsen-Saines K., Celentano D.D., Essex M., Hudelson S.E., Redd A.D., Fleming T.R. HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission. N. Engl. J. Med., 2016, vol. 375, no. 9, pp. 830— 839. doi: 10.1056/nejmoa1600693
  7. Global HIV & AIDS statistics — 2018 fact sheet UNAIDS. URL: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_ru.pdf
  8. Harman S., Herrera C., Armanasco N., Nuttall J., Shattock R.J. Preclinical evaluation of the HIV-1 fusion inhibitor L’644 as a potential candidate microbicide. Antimicrob. Agents Chemother., 2012, vol. 56, no. 5, pp. 4381—4390. doi: 10.1128/AAC.06108-11
  9. Kobayashi M., Yoshinaga T., Seki T., Wakasa-Morimoto C., Brown K.W., Ferris R., Foster S.A., Hazen R.J., Miki S., Suyama-Kagitani A., Kawauchi-Miki S. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother., 2011, vol. 55, no. 2, pp. 813—821. doi: 10.1128/AAC.01209-10
  10. Marsden M.D., Avancena P., Kitchen C.M., Hubbard T., Zack J.A. Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob. Agents Chemother., 2011, vol. 55, no. 8, pp. 3696—3702. doi: 10.1128/AAC.00566-11
  11. Parkin N.T., Hellmann N.S., Whitcomb J.M., Kiss L., Chappey C., Petropoulos C.J. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 2004, vol. 48, no. 2, pp. 437—443. doi: 10.1128/aac.48.2.437-443.2004
  12. Quashie P.K., Oliviera M., Veres T., Osman N., Han Y.S., Hassounah S., Lie Y., Huang W., Mesplede T., Wainberg M.A. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J. Virol., 2015, vol. 89, no. 6,pp. 3163-3175. doi: 10.1128/JVI.03353-14
  13. Reuman E.C., Bachmann M.H., Varghese V., Fessel W.J., Shafer R.W. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob. Agents Chemother., 2010, vol. 54, no. 2, pp. 934-936. doi: 10.1128/AAC.01345-09
  14. Rodriguez M.A., Chen Y., Craigo J.K., Chatterjee R., Ratner D., Tatsumi M., Roy P., Neogi D., Gupta P. Construction and characterization of an infectious molecular clone of HIV-1 subtype A of Indian origin. Virology, 2006, vol. 345, pp. 328-336. doi: 10.1016/j.virol.2005.09.053
  15. Uckun F.M., Cahn P., Qazi S. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Expert Opin. Investig. Drugs, 2012, vol. 21, no. 4, pp. 489-500. doi: 10.1517/13543784.2012.664635

Copyright (c) 2020 Zyryanova D.P., Bogacheva N.V., Totmenin A.V., Gashnikova N.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies